PEPG earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -0.99. Updated 2026-07-23.
PepGen (PEPG) Research Hub
PepGen (PEPG) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 2.98 USD (-5.40%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.99, market cap 0.14B. This hub links to the full technical, earnings and options research available for PEPG.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 2.98 USD (-5.40%) |
| 52-week range | 1.49 USD – 3.57 USD |
| Trend regime | Range |
| 14-day RSI | 54.5 (Neutral) |
| Trailing P/E | -0.99 |
| Market cap | 0.14B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for PEPG
Covered Call on PEPG: how it works, illustrative setup around the real 2.98 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on PEPG: how it works, illustrative setup around the real 2.98 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on PEPG: how it works, illustrative setup around the real 2.98 USD price, max profit/loss, breakeven and when to use it. Educational.
PEPG technical analysis: range, last 2.98 USD, RSI 54.5, 52w range 1.49 USD–3.57 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is PEPG in?
PepGen (PEPG) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is PEPG in an uptrend or downtrend?
As of 2026-09-11, PEPG is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is PEPG's trailing P/E ratio?
PEPG's trailing P/E is -0.99, with a market cap of 0.14B. See the earnings research page for full valuation detail.
When does PEPG next report earnings?
PEPG is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -0.3 USD.